Pressemitteilung BoxID: 585420 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Marc Heydrich
  • +49 (30) 75019-134

Increased EBITDA-Forecast for Q1 to EUR 3.1 million

(PresseBox) (Berlin, ) Preliminary figures show that aap Implantate AG (XETRA: AAQ.DE) increased the EBITDA in the first quarter of the financial year 2013 to around EUR 3.1 million, up by 48% on the previous year's EUR 2.1 million, while sales totalling around EUR 10.4 million (previous year: EUR 9.9 million). Its previous EBITDA forecast was between EUR 1.5 million and EUR 1.9 million. The EBITDA increase was due to the favourable development of achieving milestones sooner than expected.

For the full financial year 2013, the Management Board reaffirms for now its sales growth forecast of at least 10% to around EUR 40.0 million and its EBITDA growth forecast of at least 15% to over EUR 7.0 million. As already noted in the consolidated financial statements, quarterly fluctuations in growth and profitability are to be expected in view of the product and project sales mix.

Publication of the interim report for the first quarter of 2013 is scheduled for 15 May 2013.

This release contains forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

aap Implantate AG

Prime Standard/Regulated Market - All German stock markets

aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company’s products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company’s products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap’s stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit, or download the Company’s investor relations app from the Apple’s App Store or Google Play.